Source:http://linkedlifedata.com/resource/chembl/assay/description
| Subject | Object |
|---|---|
| assay:41573 |
Butyrylcholinesterase
|
| assay:48195 |
Corticosteroid binding globulin
|
| assay:1 |
The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM
|
| assay:2 |
Compound was evaluated for its ability to mobilize calcium in 1321NI cells
|
| assay:4 |
Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680
|
| assay:5 |
In vitro cell cytotoxicity against 143-B cell lines(Human osteosarcoma cell line)
|
| assay:6 |
In vitro cell cytotoxicity against 143-B cell lines(Human osteosarcoma cell line)
|
| assay:7 |
Cytotoxic Activity was evaluated against 143B (TK-) tumor cells
|
| assay:8 |
In vitro cell cytotoxicity was determined against 143B cell line
|
| assay:9 |
Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound
|
| assay:10 |
In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK
|
| assay:11 |
In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK
|
| assay:12 |
In vitro cell cytotoxicity was determined against 143B-LTK cell line
|
| assay:13 |
The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus
|
| assay:14 |
The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus
|
| assay:15 |
The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus
|
| assay:16 |
The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus
|
| assay:17 |
Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase
|
| assay:18 |
Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO)
|
| assay:19 |
Inhibition of partially purified 15-lipoxygenase from human leukocytes
|
| assay:20 |
Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO)
|
| assay:22 |
Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO)
|
| assay:21 |
Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO)
|
| assay:23 |
Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO) ;NI is no inhibition
|
| assay:24 |
Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition
|
| assay:25 |
Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.
|
| assay:26 |
In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase
|
| assay:27 |
Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM)
|
| assay:28 |
Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes
|
| assay:29 |
Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean
|
| assay:30 |
Inhibitory activity against soybean 15-lipoxygenase was evaluated
|
| assay:31 |
Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM
|
| assay:32 |
The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM
|
| assay:33 |
The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM
|
| assay:34 |
Compound was tested in vitro for inhibition of 15-lipoxygenase soybean
|
| assay:35 |
Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean
|
| assay:36 |
Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase
|
| assay:37 |
Binding affinity against bacterial 16S rRNA using mass spectrometry based assay
|
| assay:38 |
Dissociation constant with dimeric 16S rRNA RNA construct B
|
| assay:39 |
Dissociation constant towards 16S rRNA construct A
|
| assay:40 |
Dissociation constant towards 16S rRNA construct B
|
| assay:41 |
Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli
|
| assay:42 |
Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli
|
| assay:43 |
Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2)
|
| assay:51 |
Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2)
|
| assay:44 |
Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2)
|
| assay:45 |
The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes
|
| assay:46 |
The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes
|
| assay:47 |
Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation
|
| assay:48 |
Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation
|
| assay:49 |
Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM
|
| assay:50 |
Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM
|
| assay:52 |
Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1)
|
| assay:53 |
Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration
|
| assay:54 |
Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration
|
| assay:55 |
Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes
|
| assay:149306 |
Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes
|
| assay:56 |
Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined
|
| assay:57 |
Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype
|
| assay:58 |
Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor
|
| assay:59 |
Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor
|
| assay:60 |
In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation
|
| assay:61 |
In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation
|
| assay:62 |
Cytotoxic activity against human ovarian cancer (1A9) cell line
|
| assay:63 |
Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined
|
| assay:64 |
Effective dose of compound against replication of 1A9 cell line was evaluated
|
| assay:65 |
In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line
|
| assay:66 |
In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line)
|
| assay:67 |
In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active
|
| assay:68 |
In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL
|
| assay:69 |
Inhibitory activity against Taxol resistant 1A9 cell lines
|
| assay:70 |
Cytotoxicity against human ovarian cancer (1A9) cell lines.
|
| assay:71 |
Percentage inhibition of human ovarian cancer (1A9) cell lines.
|
| assay:72 |
Effective dose required for inhibitory activity against 1A9 human tumor cell line.
|
| assay:73 |
Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL
|
| assay:74 |
Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL
|
| assay:75 |
Percent inhibition against 1A9 human tumor cell line at >10 ug/mL
|
| assay:76 |
Inhibitory concentration against Jurkat cells
|
| assay:92487 |
Inhibitory concentration against Jurkat cells
|
| assay:77 |
In vitro anticancer activity against 2 SCLC cell line; inactive
|
| assay:78 |
Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase
|
| assay:79 |
In vitro inhibition of human 2,3-oxidosqualene cyclase.
|
| assay:80 |
In vitro inhibition of human 2,3-oxidosqualene cyclase.
|
| assay:81 |
In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.
|
| assay:82 |
Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes
|
| assay:83 |
Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes
|
| assay:84 |
Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes
|
| assay:85 |
Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes
|
| assay:86 |
Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes
|
| assay:87 |
Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase
|
| assay:88 |
Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)
|
| assay:89 |
Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki
|
| assay:90 |
Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes
|
| assay:91 |
Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes
|
| assay:92 |
Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes
|
| assay:93 |
Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease)
|
| assay:94 |
Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex
|
| assay:95 |
In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line
|
| assay:96 |
50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.
|
| assay:97 |
Antiviral activity against Hepatitis B virus in 2.2.15 cell line
|